Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer

  • Authors:
    • Kiyoshi Yoshino
    • Ayako Hosoi
    • Keigo Osuga
    • Takayuki Enomoto
    • Yutaka Ueda
    • Kenjiro Sawada
    • Seiji Mabuchi
    • Eiji Kobayashi
    • Koji Matsuo
    • Tadashi Kimura
  • View Affiliations

  • Published online on: April 4, 2016     https://doi.org/10.3892/mco.2016.846
  • Pages: 1068-1072
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Extended wait time prior to initial surgery may increase patients' anxiety. Therefore, patients may opt to receive other available treatments to inhibit tumor growth until surgery. This retrospective study describes our experience with single‑dose intra‑arterial neoadjuvant chemotherapy (IANAC) to more effectively utilize the wait time prior to radical hysterectomy. A total of 12 patients with International Federation of Gynecology and Obstetrics stage IB1‑IIB cervical cancer were treated with single‑dose IANAC prior to radical hysterectomy. Cisplatin and paclitaxel were administered intra‑arterially or intravenously, respectively. the surgical outcome, prognosis and factors affecting disease recurrence were compared between these 12 patients and 57 patients in a primary surgery alone (PS) control group. As regards surgical outcome, there were no significant differences between the two groups. During the postoperative follow‑up period (median, 41 months), disease recurrence was observed in 5̸12 (41.6%) IANAC cases and in 22̸57 (38.5%) PS cases (median follow‑up, 54 months). There was no significant difference in disease‑free survival (DFS) or 3‑year survival rates between IANAC and PS (91.6 vs. 71.9%, respectively). The multivariate analysis demonstrated that wait time duration (≥45 vs. <45 days) and the use of IANAC did not affect DFS. Only tumor histology (squamous vs. non‑squamous) was found to be an independent prognostic factor for DFS (hazard ratio = 0.35, 95% confidence inerval: 0.145‑0.8967, P=0.0292). In addition, distal recurrence was statistically more frequent in the IANAC group compared with that in the PS group (P=0.0405). Therefore, single‑cycle IANAC should not be performed without careful consideration.
View Figures
View References

Related Articles

Journal Cover

June 2016
Volume 4 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yoshino, K., Hosoi, A., Osuga, K., Enomoto, T., Ueda, Y., Sawada, K. ... Kimura, T. (2016). Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer. Molecular and Clinical Oncology, 4, 1068-1072. https://doi.org/10.3892/mco.2016.846
MLA
Yoshino, K., Hosoi, A., Osuga, K., Enomoto, T., Ueda, Y., Sawada, K., Mabuchi, S., Kobayashi, E., Matsuo, K., Kimura, T."Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer". Molecular and Clinical Oncology 4.6 (2016): 1068-1072.
Chicago
Yoshino, K., Hosoi, A., Osuga, K., Enomoto, T., Ueda, Y., Sawada, K., Mabuchi, S., Kobayashi, E., Matsuo, K., Kimura, T."Single‑dose intra‑arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB‑IIB cervical cancer". Molecular and Clinical Oncology 4, no. 6 (2016): 1068-1072. https://doi.org/10.3892/mco.2016.846